Open Access
Volume 26, 2019
Article Number 9
Number of page(s) 11
Published online 27 February 2019
  1. Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ. 2005. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunology Letters, 101(2), 226–230. [CrossRef] [PubMed] [Google Scholar]
  2. Antoniazi S, Price HP, Kropf P, Freudenberg MA, Galanos C, Smith DF, Müller I. 2004. Chemokine gene expression in toll-like receptor-competent and -deficient mice infected with Leishmania major. Infection and Immunity, 72, 5168–5174. [CrossRef] [PubMed] [Google Scholar]
  3. Aoun K, Bouratbine A, Harrat Z, Guizani I, Mokni M, Bel Hadj Ali S, Ben Osman A, Belkaïd M, Dellagi K, Ben Ismaïl R. 2000. Données épidémiologiques et parasitologiques concernant la leishmaniose cutanée sporadique du nord tunisien. Bulletin de la Société de Pathologie Exotique, 93(2), 101–103. [Google Scholar]
  4. Aoun K, Bouratbine A. 2014. Cutaneous leishmaniasis in North Africa: a review. Parasite, 21, 14. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. BenSaid M, Guerbouj S, Saghrouni F, Fathallah-Mili A, Guizani I. 2006. Occurrence of Leishmania infantum cutaneous leishmaniasis in central Tunisia. Transaction of the Royal Society of Tropical Medicine and Hygiene, 100(6), 521–526. [CrossRef] [Google Scholar]
  6. Bettaieb J, Toumi A, Chlif S, Chelghaf B, Boukthir A, Gharbi A, Ben Salah A. 2014. Prevalence and determinants of Leishmania major infection in emerging and old foci in Tunisia. Parasites & Vectors, 7(1), 386. [CrossRef] [PubMed] [Google Scholar]
  7. Bouratbine A, Aoun K, Ghrab J, Harrat Z, Ezzedini MS, Etlijani S. 2005. Spread of Leishmania killicki to Central and South West Tunisia. Parasite, 12(1), 59–63. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  8. Bourreau E, Prévot G, Gardon J, Pradinaud R, Launois P. 2001. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. Journal of Infectious Disease, 184(12), 1628–1630. [CrossRef] [Google Scholar]
  9. Bourreau E, Pascalis H, Prévot G, Kariminia A, Jolly N, Milon G, Buffet P, Michel R, Meynard JB, Boutin JP, Aschimoff D, Launois P. 2003. Th2 responses predominate during the early phases of infection in patients with localized cutaneous leishmaniasis and precede the development of Th1 responses. Infection and Immunity, 71(4), 2244–2246. [CrossRef] [PubMed] [Google Scholar]
  10. Bousslimi N, Aoun K, Ben-Abda I, Ben-Alaya-Bouafif N, Raouane M, Bouratbine A. 2010. Epidemiologic and clinical features of cutaneous leishmaniasis in southeastern Tunisia. American Journal of Tropical Medicine and Hygiene, 83(5), 1034–1039. [CrossRef] [Google Scholar]
  11. Brodskyn CI, Barral A, Boaventura V, Carvalho E, Barral-Nett M. 1997. Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. Journal of Immunology, 159, 4467–4473. [Google Scholar]
  12. Cáceres-Dittmar G, Tapia FJ, Sánchez MA, Yamamura M, Uyemura K, Modlin RL, Bloom BR, Convit J. 1993. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clinical Experimental Immunology, 91(3), 500–505. [CrossRef] [Google Scholar]
  13. Costa-Silva MF, Gomes LI, Martins-Filho OA, Rodrigues-Silva R, Freire Jde M, Quaresma PF, Pascoal-Xavier MA, Mendes TA, Serakides R, Zauli DA, Campi-Azevedo AC, Melo MN, Gontijo CM, Peruhype-Magalhães V, Teixeira-Carvalho A. 2014. Gene expression profile of cytokines and chemokines in skin lesions from Brazilian Indians with localized cutaneous leishmaniasis. Molecular Immunology, 57(2), 74–85. [CrossRef] [PubMed] [Google Scholar]
  14. Cummings HE, Tuladhar R, Satoskar AR. 2010. Cytokines and their STATs in cutaneous and visceral leishmaniasis. Journal of Biomedicine and Biotechnology, 2010, 294389. [CrossRef] [Google Scholar]
  15. Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinho-Ribeiro V, Azeredo-Coutinho RB, Coutinho SG. 2002. T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clinical and Diagnostic Laboratory Immunology, 9(2), 251–256. [PubMed] [Google Scholar]
  16. Dutra WO, Faria DR, Lima Machado PR, Guimarães LH, Schriefer A, Carvalho E, Gollob KJ. 2011. Immunoregulatory and effector activities in human cutaneous and mucosal leishmaniasis: understanding mechanisms of pathology. Drug Development Research, 72(6), 430–436. [CrossRef] [PubMed] [Google Scholar]
  17. Faria DR, Gollob KJ, Barbosa J, Jr., Schriefer A, Machado PR, Lessa H, Carvalho LP, Romano-Silva MA, de Jesus AR, Carvalho EM, Dutra WO. 2005. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infection and Immunity, 73(12), 7853–7859. [CrossRef] [PubMed] [Google Scholar]
  18. Faria DR, Souza PE, Durães FV, Carvalho EM, Gollob KJ, Machado PR, Dutra WO. 2009. Recruitment of CD8 T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis. Parasite Immunology, 31, 432–439. [CrossRef] [PubMed] [Google Scholar]
  19. Goncalves R, Zhang X, Cohen H, Debrabant A, Mosser DM. 2011. Platelet activation attracts a subpopulation of effector monocytes to sites of Leishmania major infection. Journal of Experimental Medicine, 208, 1253–1265. [CrossRef] [Google Scholar]
  20. Gollob KJ, Viana AG, Dutra WO. 2014. Immunoregulation in human American leishmaniasis: balancing pathology and protection. Parasite Immunology, 36(8), 367–376. [CrossRef] [PubMed] [Google Scholar]
  21. Haouas N, Gorcii M, Chargui N, Aoun K, Bouratbine A, Messaadi Akrout F, Masmoudi A, Zili J, Ben Said M, Pratlong F, Dedet JP, Mezhoud H, Azaiez R, Babba H. 2007. Leishmaniasis in central and southern Tunisia: current geographical distribution of zymodemes. Parasite, 14(3), 239–246. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  22. Jardim A, Funk V, Caprioli RM, Olafson RW. 1995. Isolation and structural characterisation of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochemistry Journal, 305, 307–313. [CrossRef] [Google Scholar]
  23. Louzir H, Melby PC, Ben Salah A, Marrakchi H, Aoun K, Ben Ismail R, Dellagi K. 1998. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. Journal of Infectious Disease, 177, 1687–1695. [CrossRef] [Google Scholar]
  24. Luster AD. 1998. Chemokines: chemotactic cytokines that mediate inflammation. New England Journal of Medicine, 338, 436–445. [CrossRef] [Google Scholar]
  25. Martins AL, Barreto JA, Lauris JR, Martins AC. 2014. American tegumentary leishmaniasis: correlations among immunological, histopathological and clinical parameters. Anais Brasileiros De Dermatologia, 89(1), 52–58. [CrossRef] [PubMed] [Google Scholar]
  26. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV, Palomo-Cetina A. 1994. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infection and Immunity, 62(3), 837–842. [PubMed] [Google Scholar]
  27. Modlin RL, Tapia FJ, Bloom BR, Gallinoto ME, Castes M, Rondon AJ, Rea TH, Convit J. 1985. In situ characterization of the cellular immune response in American cutaneous leishmaniasis. Clinical and Experimental Immunology, 60(2), 241–248. [PubMed] [Google Scholar]
  28. Mokni M, Mebazaa A, Boubaker S. 2011. Histology of cutaneous leishmaniasis. Annales de Dermatologie et de Vénéréologie, 138(4), 354–356. [CrossRef] [Google Scholar]
  29. Nicolas L, Prina E, Lang T, Milon G. 2002. Real-time PCR for detection and quantification of Leishmania in mouse tissues. Journal of Clinical Microbiology, 40, 1666–1669. [CrossRef] [PubMed] [Google Scholar]
  30. Nilsen R, Mshana RN. 1987. In situ characterization of the cutaneous immune response in Ethiopian cutaneous leishmaniasis. Scandinavian Journal of Immunology, 26(5), 503–512. [CrossRef] [PubMed] [Google Scholar]
  31. Nylén S, Eidsmo L. 2012. Tissue damage and immunity in cutaneous leishmaniasis. Parasite Immunology, 34(12), 551–561. [CrossRef] [PubMed] [Google Scholar]
  32. Pereira-Carvalho R, Mendes-Aguiar CO, Oliveira-Neto MP, Covas CJ, Bertho AL, Da-Cruz AM, Gomes-Silva A. 2013. Leishmania braziliensis-reactive T cells are down-regulated in long-term cured cutaneous leishmaniasis, but the renewal capacity of T effector memory compartments is preserved. PLoS One, 8(11), e81529. [CrossRef] [PubMed] [Google Scholar]
  33. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceição-Silva F, Modlin RL. 1993. Cytokine patterns in the pathogenesis of human leishmaniasis. Journal of Clinical Investigation, 91(4), 1390–1395. [CrossRef] [Google Scholar]
  34. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. 2007. Cutaneous leishmaniasis. Lancet Infectious Diseases, 7(9), 581–596. [CrossRef] [PubMed] [Google Scholar]
  35. Ritter U, Moll H, Laskay T, Brocker E, Velazco O, Becker I, Gillitzer R. 1996. Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis. Journal of Infectious Diseases, 173, 699–709. [CrossRef] [Google Scholar]
  36. Ritter U, Moll H. 2000. Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN-γ and is antagonized by IL-4. European Journal of Immunology, 30, 3111–3120. [CrossRef] [PubMed] [Google Scholar]
  37. Ritter U, Körner H. 2002. Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis. Parasite Immunology, 24(6), 295–301. [CrossRef] [PubMed] [Google Scholar]
  38. Russo J, Sheriff F, Lopez de Cicco R, Pogash TJ, Nguyen T, Russo IH. 2014. Methodology for studying the compartments of the human breast, in Techniques and Methodological Approaches in Breast Cancer Research, Russo J, Russo IH, Editors. Erwei Song, Hai Hu. p. 75–102. [CrossRef] [Google Scholar]
  39. Salah AB, Kamarianakis Y, Chlif S, Alaya NB, Prastacos P. 2007. Zoonotic cutaneous leishmaniasis in central Tunisia: spatio temporal dynamics. International Journal of Epidemiology, 36(5), 991–1000. [CrossRef] [PubMed] [Google Scholar]
  40. Scott P. 2005. Immunologic memory in cutaneous leishmaniasis. Cellular Microbiology, 7(12), 1707–1713. [CrossRef] [PubMed] [Google Scholar]
  41. Scott P, Novais FO. 2016. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nature Reviews Immunology, 16(9), 581–592. [CrossRef] [PubMed] [Google Scholar]
  42. Teixeira MJ, Teixeira CR, Andrade BB, Barral-Netto M, Barral A. 2006. Chemokines in host-parasite interactions in leishmaniasis. Trends in Parasitology, 22, 32–40. [CrossRef] [PubMed] [Google Scholar]
  43. Valencia-Pacheco G, Loría-Cervera EN, Sosa-Bibiano EI, Canché-Pool EB, Vargas-Gonzalez A, Melby PC, Andrade-Narvaez FJ. 2014. In situ cytokines (IL-4, IL-10, IL-12, IFN-γ) and chemokines (MCP-1, MIP-1α) gene expression in human Leishmania (Leishmania) mexicana infection. cytokine, 69(1), 56–61. [CrossRef] [Google Scholar]
  44. Zaph C, Uzonna J, Beverley SM, Scott P. 2004. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nature Medicine, 10(10), 1104–1110. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.